IgorIvanovichRybkinMDPhD

Clinical Trials

• A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09

  Completed

  Phase 3

• Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08

  Completed

• Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) Start of enrollment: 2015 Jun 11

  Completed

  Phase 2

• A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer Start of enrollment: 2015 Mar 01

  Completed

  Phase 1, Phase 2

• BIO 300 Non-Small Cell Lung Cancer Study Start of enrollment: 2015 Nov 01

  Completed

  Phase 1, Phase 2

• Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2016 Feb 15

  Completed

  Phase 2

• Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Start of enrollment: 2017 Aug 01

  Completed

  Phase 2, Phase 3

• eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients Start of enrollment: 2016 Jun 01

  Active, not recruiting

  Phase 3

• Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01

  Completed

  Phase 2

• Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01

  Completed

  Phase 2, Phase 3

• Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29

  Active, not recruiting

  Phase 3

• An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer Start of enrollment: 2016 Dec 20

  Active, not recruiting

  Phase 1, Phase 2

• Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer Start of enrollment: 2016 Nov 07

  Terminated

  Phase 2

• A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2017 Mar 04

  Active, not recruiting

  Phase 3

• PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients Start of enrollment: 2017 May 24

  Terminated

  Phase 1

• A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) Start of enrollment: 2017 May 02

  Completed

  Phase 3

• First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590) Start of enrollment: 2017 Jul 25

  Completed

  Phase 3

• A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC Start of enrollment: 2017 Aug 24

  Active, not recruiting

  Phase 3

• Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC Start of enrollment: 2018 Mar 09

  Enrolling by invitation

  Early Phase 1

• Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2018 Mar 19

  Terminated

  Phase 2

• Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2018 Mar 22

  Terminated

  Phase 2

• Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) Start of enrollment: 2018 Apr 24

  Active, not recruiting

  Phase 3

• A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Start of enrollment: 2018 Sep 06

  Active, not recruiting

  Phase 1, Phase 2

• Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions Start of enrollment: 2019 Mar 13

  Terminated

  Phase 2

• M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2019 Apr 16

  Terminated

  Phase 2

• Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors Start of enrollment: 2021 Jan 26

  Recruiting

  Phase 2

• A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2021 Dec 20

  Recruiting

  Phase 3

• Join now to see all